for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Consort Medical plc

CSRT.L

Latest Trade

758.00GBp

Change

8.00(+1.07%)

Volume

18,598

Today's Range

754.00

 - 

780.00

52 Week Range

700.00

 - 

1,210.00

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
750.00
Open
754.00
Volume
18,598
3M AVG Volume
1.11
Today's High
780.00
Today's Low
754.00
52 Week High
1,210.00
52 Week Low
700.00
Shares Out (MIL)
49.36
Market Cap (MIL)
374.18
Forward P/E
14.35
Dividend (Yield %)
--

Latest Developments

More

Consort Medical Says Now Expects Cramlington Incident To Hit Oper. Profit By 7-9 Mln Stg

Consort Medical Says Incident At Cramlington Facility To Hit FY Profit By 3-5 Mln Stg

Consort Medical Says FY Net Debt At £97.4 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Consort Medical plc

Consort Medical PLC is a contract development and manufacturing organization (CDMO). The Company's principal activities include designing, development and manufacture of medical drug delivery devices and services for the pharmaceutical industry. The Company operates through two segments: Bespak and Aesica. Bespak's core business is the manufacture of inhaled drug delivery devices for life sciences partners and its operations are based in the United Kingdom. The Aesica business manufactures and sells active pharmaceutical ingredients (API), formulated pharmaceutical products and packaging services to the pharmaceutical industry and its operations are based in the United Kingdom and Europe. It offers its services to customers, such as pharmaceutical companies and life sciences. Its device products include metered dose inhalers, dry powder devices, actuators, dose counters, disposable auto-injectors, nasal devices and point-of-care diagnostics devices.

Industry

Medical Equipment & Supplies

Contact Info

Breakspear Park, Breakspear Way

+44.1442.867920

https://www.consortmedical.com

Executive Leadership

Christopher Brinsmead

Non-Executive independent Chairman of the Board

Jonathan M. Glenn

Chief Executive, Executive Director

Paul Andrew Hayes

Chief Financial Officer, Executive Director

Manja Boerman

President - Aesica

Keyvan Djamarani

President - Bespak

Key Stats

2.00 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, GBP)

2017

0.3K

2018

0.3K

2019

0.3K

2020(E)

0.3K
EPS (GBp)

2017

64.400

2018

63.900

2019

62.800

2020(E)

52.826
Price To Earnings (TTM)
35.66
Price To Sales (TTM)
1.23
Price To Book (MRQ)
1.57
Price To Cash Flow (TTM)
10.66
Total Debt To Equity (MRQ)
46.56
LT Debt To Equity (MRQ)
46.56
Return on Investment (TTM)
3.15
Return on Equity (TTM)
2.24

Latest News

Latest News

Consort, Opiant to develop nasal spray for opioid overdose treatment

Britain's Consort Medical Plc said on Monday it had agreed to develop a nasal spray for treating opioid overdoses with specialty pharmaceutical company Opiant Pharmaceuticals Inc.

Consort and Opiant to work on nasal spray overdose treatment

Consort Medical Plc has agreed to develop a nasal spray for treating opioid overdoses with specialty pharmaceutical company Opiant Pharmaceuticals Inc .

BRIEF-Vitec says finance head Hayes to leave for Consort Medical job

* Paul Hayes, group finance director, has informed board that he will be leaving Vitec to become chief financial officer of Consort Medical Plc

BRIEF-Consort Medical names Vitec finance head Paul Hayes as its next CFO

* Paul Hayes, finance director of Vitec Group Plc, is to succeed Richard Cotton as Consort Medical's group chief financial officer Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up